Sage Therapeutics Inc. scored a big win Thursday, disclosing positive top-line data from its pivotal program testing brexanolone in postpartum depression (PPD), results that should support regulatory filings next year and position the intravenously administered drug (previously known as SAGE-547) as potentially the first treatment specifically for PPD.
Gilead Sciences Inc. beat earnings estimates for the third quarter, but analysts seeking to tease out stabilizing trends in the company's declining hepatitis C virus (HCV) franchise were largely disappointed, while overarching concerns about the paucity of promising late-stage programs also helped drive the stock down slightly Friday. Shares of Gilead (NASDAQ:GILD) closed at $77.07, down 81 cents.
CLEVELAND – Coming into the Cleveland Clinic's 15th annual Medical Innovation Summit, gene therapy had been making headlines, most recently the unanimous recommendation by the FDA's Cellular, Tissue and Gene Therapies Advisory Committee in favor of Spark Therapeutics Inc.'s Luxturna (voretigene neparvovec) in RPE65-mediated inherited retinal disease. But back in the early 2000s, when Casey Cunningham, of Sante Ventures, was working as a clinical investigator, the gene-based technologies weren't exactly hot property.
CLEVELAND – A technology so promising it took the FDA barely 100 days to clear it for marketing approval topped the Cleveland Clinic's list of 10 innovations expected to have significant impacts on health care in 2018. Unveiled on the last day of the 15th annual Medical Innovation Summit, the list leads with the closed-loop insulin delivery system for type 1 diabetes and includes advances such as gene therapy and telehealth that have been years in the making.
CLEVELAND – A technology so promising it took the FDA barely 100 days to clear it for marketing approval topped the Cleveland Clinic's list of 10 innovations expected to have significant impacts on health care in 2018. Unveiled on the last day of the 15th annual Medical Innovation Summit, the list leads with the closed-loop insulin delivery system for type 1 diabetes and includes advances such as gene therapy and telehealth that have been years in the making.
CLEVELAND – Cleveland Clinic CEO Toby Cosgrove called genomics and precision medicine the "fastest-moving elements of today's medical universe. Barely on the radar 15 years ago, today they fill the screen." As this year's focus at the Medical Innovations Summit, genomics and precision medicine are considered the future in health care, but, as many panelists noted, as the technology side of the equation continues advancing toward the end goal, clinicians and regulators will need to keep up.
CLEVELAND – If the health care industry were a baseball game, it would currently be in the third inning, said Cleveland Clinic President and CEO Delos "Toby" Cosgrove, who told attendees of the 15th Medical Innovation Summit kicked off Monday he is "always stunned by the data [and by] how fast knowledge is accumulating."
